TB-500 — Wolverine Health

How it works

A synthetic fragment mimicking Thymosin Beta-4, a protein that regulates actin dynamics and supports cell migration during tissue repair. Animal studies show it accelerates wound healing, reduces inflammation, and promotes angiogenesis. Human evidence is limited to small trials and case series — the data is promising in the lab, thin in the clinic.

FDA status: No FDA approval. Under PCAC July 23–24 2026 review for 503A bulk substance consideration.
WADA status: Prohibited in sport
Route: subcutaneous injection

Key studies

Thymosin beta 4 accelerates wound healing — Goldstein et al.

Thymosin beta-4 is a ubiquitous actin-sequestering protein that modulates cell migration and proliferation during wound healing and tissue repair in animal models.

Safety

WADA Prohibited List 2026. No long-term human safety data. The immunomodulatory and angiogenic mechanisms are well-established in animals; human extrapolation remains speculative.

Wolverine Health is building physician-supervised peptide protocols. Get early access.

Join the waitlist

Research on TB-500

Peptide access by US state: why the regulatory patchwork right now is real

The federal compounding framework applies the same way in every state. The state pharmacy boards do not. The result is a real state-by-state patchwork that decides whether a telehealth prescription for a compounded peptide is actually fillable where you live.

503B outsourcing pharmacies and compounded peptides: the regulatory gap that still matters

Section 503B outsourcing facilities are the higher-volume, FDA-inspected cousin of the corner compounding pharmacy. The 503B Bulks List is its own regulatory pipeline — and it changes what an actual peptide supply chain looks like when one opens.

After the PCAC votes: what FDA reclassification actually looks like in practice

A favourable July PCAC vote is not a prescription you can fill in August. The rulemaking that follows the recommendation is where the access actually changes — and where the legitimate supply chain starts to exist.

The PCAC review is July 23–24, 2026. Here is what that means for peptide access.

Two days at FDA's White Oak campus decide which of seven peptides US compounding pharmacies will be allowed to dispense by prescription. The vote is not an approval, the docket is not all the peptides, and the framing the forums use is mostly wrong.

How peptides influence collagen synthesis: the mechanism behind the claims

WADA

Three peptides under FDA review have animal-model evidence touching collagen biology — BPC-157, GHK-Cu, and TB-500. The mechanism story varies per peptide. The human evidence does not. Here is what collagen is and where the prescribing files diverge.

Angiogenesis and peptide therapy: what new blood-vessel growth has to do with recovery

WADA

Two peptides on the July 2026 FDA review docket — BPC-157 and TB-500 — rest their entire animal mechanism story on the same biology: new blood-vessel growth into damaged tissue. Here is what that means, where the human evidence sits, and the open question angiogenesis always raises.

BPC-157 vs TB-500 for injury recovery: what the evidence actually separates

WADA

BPC-157 and TB-500 get sold side-by-side as the injury-recovery peptide stack. Two different proteins, two different evidence bases, two different gaps. Here is what the published data actually says — and where the July 2026 FDA review treats them as one regulatory question.

TB-500 and tendon repair: what the research actually says about the protein your tendons were already making

WADA

TB-500 has a reputation for pulling tendons back from chronic pain. The underlying protein is real. The tendon-specific evidence is thinner than the forums imply. Here is what the research actually shows, what nobody has tested in a human tendon, and how the July 2026 FDA review fits.

TB-500 / Thymosin Beta-4: Tissue Repair Research and Regulatory Overview

WADA

Science-journalism overview of TB-500 (Thymosin Beta-4) research — what animal and limited human data suggest about tissue repair, and where the compound stands under PCAC July 2026 review.